Covance Inc., a drug development services company, provides various early-stage and late-stage product development services primarily to the pharmaceutical, biotechnology, and medical device industries worldwide. Its early development services include preclinical services, such as toxicology, pharmaceutical and nutritional chemistry, polyclonal and monoclonal antibody, immunology and antibody, metabolism studies and pharmacokinetic screening, and bioanalytical testing services; and clinical pharmacology services comprising first-in-human trials of new pharmaceuticals. The company’s late-stage development services include central laboratory services to biotechnology and pharmaceutical customers; and clinical development services, such as the full management of Phase II through IV clinical studies, study design and modeling, co-ordination of study activities, trial logistics, monitoring of study site performance, clinical data management and biostatistical analysis, medical writing and regulatory services, and periapproval services. It also offers market access services, including reimbursement and healthcare economics consulting services, which comprise outcomes and pharmacoeconomic studies, reimbursement planning, reimbursement advocacy programs, risk evaluation and mitigation strategy services, registry services, and specialty pharmacy services; and clinical trial support services, such as cardiac safety services, and interactive voice and Web response services. In addition, Covance Inc. offers laboratory testing services to the chemical, agrochemical, and food industries. The company was founded in 1987 and is headquartered in Princeton, New Jersey.